To pay or not to pay: measuring risk preferences in lab and field

Measuring risk preferences using monetary incentives is costly. In the field, it might be also unfair and unsafe. The commonly used measure of Holt and Laury (2002) relies on a dozen lottery choices and payments, which make it time consuming and expensive. It also raises moral concerns as a result of the unequal payments generated by good and bad luck. Paying some but not all subjects may also create tensions between the researcher and subjects. In a pre-registered study in Honduras, Nigeria and Spain, we use a short version of Holt and Laury where we address all three concerns. We find in the field that not paying at all or paying with and without probabilistic rules makes no difference. Our hypothetical and short version makes our measurement of risk cheaper, fairer and safer

Optimización de un método para la determinación de la peroxidación lipídica en suero humano

A variety of free radicals are produced in human organism as a consequence of normal cell metabolism. These free radicals are generally removed by endogenous scavengers but also can interact with plasma and tisular lipids causing its peroxidation. It is very difficult to determine the magnitude of the peroxidation and also the first lipidic peroxidation products due to their very short half-life. However the evaluation of the secondary lipidic peroxidation products can be quantitatively determined as well as their degradation products such as aldehydes with high reactivity among them malondialdehyde (MDA) is the most relevant. Among the variety of assays developed to estimate the magnitude of oxidative damage in humans, the most commonly employed is based on the reaction of endogenous malondialdehyde (MDA) with 2-thiobarbituric acid (TBA). This reaction yields very stable cromogenic and fluorogenic MDA-TBA adducts, that are detectable by UV spectrophotometry and fluorimetry. In the present study, a colorimetric method described by ASAKAWA and MATSUSHITA, was optimized to determine the human serum lipoperoxides based on the TBA reaction. The reaction conditions established by these authors were rigorously investigated in order to optimize this procedure. Mainly, changes were introduced relating to the reaction time and the lipoperoxides extraction method.Como consecuencia del metabolismo celular normal, se producen radicales libres que generalmente son eliminados por receptores endógenos pero también pueden interaccionar con los lípidos séricos y tisulares provocando su peroxidación. Dada la naturaleza inestable de los productos de la peroxidación lipídica resulta dificultoso determinar la magnitud de dicha peroxidación. Es, sin embargo, más accesible determinar los productos de su degradación metabólica, constituidos fundamentalmente por aldehídos de alta capacidad reactiva, siendo el más significativo el malondialdehído (MDA). Entre la variedad de métodos analíticos desarrollados para determinar el daño oxidativo de los lípidos, el más comúnmente utilizado se basa en la reacción del malondialdehído con el ácido 2-tiobarbitúrico (TBA) para formar aductos cromógenos y fluorescentes de MDA-TBA muy estables y que se pueden cuantificar por espectrofotometría de absorción visible o por fluorimetría. En el presente trabajo, para la determinación de lipoperóxidos en suero humano se ha empleado una técnica colorimétrica basada en la reacción del TBA descrita por ASAKAWA y MATSUSHITA. Para la optimización de esta técnica fueron cuidadosamente analizadas las condiciones de reacción establecidas por estos autores introduciéndose modificaciones que afectan principalmente al tiempo de reacción y al método de extracción de los lipoperóxidos

Process-generated nanoparticles from ceramic tile sintering: Emissions, exposure and environmental release

Under a Creative Commons license.-- et al.The ceramic industry is an industrial sector in need of significant process changes, which may benefit from innovative technologies such as laser sintering of ceramic tiles. Such innovations result in a considerable research gap within exposure assessment studies for process-generated ultrafine and nanoparticles. This study addresses this issue aiming to characterise particle formation, release mechanisms and their impact on personal exposure during a tile sintering activity in an industrial-scale pilot plant, as a follow-up of a previous study in a laboratory-scale plant. In addition, possible particle transformations in the exhaust system, the potential for particle release to the outdoor environment, and the effectiveness of the filtration system were also assessed. For this purpose, a tiered measurement strategy was conducted. The main findings evidence that nanoparticle emission patterns were strongly linked to temperature and tile chemical composition, and mainly independent of the laser treatment. Also, new particle formation (from gaseous precursors) events were detected, with nanoparticles  87% efficiency in particle number concentrations removal.This work was supported by the European Commission FP7 (FP7-PEOPLE-2012-ITN) Marie Curie ITN project no. 315760 (HEXACOMM) and by the Spanish MINECO (PCIN-2015-173-C02-01) under the frame of SIINN, the ERA-NET for a Safe Implementation of Innovative Nanoscience and Nanotechnology, through SIINN-ERANET project CERASAFE (id.:16). Additional support was provided by LIFE projects AIRUSE (LIFE11 ENV/ES/584), CERAMGLASS (LIFE11 ENV/ES/560) and LASERFIRING (LIFE09 ENV/ES/435).Peer Reviewe

Process-generated nanoparticles from ceramic tile sintering : Emissions, exposure and environmental release

The ceramic industry is an industrial sector in need of significant process changes, which may benefit from innovative technologies such as laser sintering of ceramic tiles. Such innovations result in a considerable research gap within exposure assessment studies for process-generated ultrafine and nanoparticles. This study addresses this issue aiming to characterise particle formation, release mechanisms and their impact on personal exposure during a tile sintering activity in an industrial-scale pilot plant, as a follow-up of a previous study in a laboratory-scale plant. In addition, possible particle transformations in the exhaust system, the potential for particle release to the outdoor environment, and the effectiveness of the filtration system were also assessed. For this purpose, a tiered measurement strategy was conducted. The main findings evidence that nanoparticle emission patterns were strongly linked to temperature and tile chemical composition, and mainly independent of the laser treatment. Also, new particle formation (from gaseous precursors) events were detected, with nanoparticles A potential risk for nanoparticle and ultrafine particle release to the environment was also identified, despite the fact that the efficiency of the filtration system was successfully tested and evidenced a >87% efficiency in particle number concentrations removal. (C) 2016 The Authors. Published by Elsevier B.V.Peer reviewe

Mytilus galloprovincialis Myticin C: A Chemotactic Molecule with Antiviral Activity and Immunoregulatory Properties

Previous research has shown that an antimicrobial peptide (AMP) of the myticin class C (Myt C) is the most abundantly expressed gene in cDNA and suppressive subtractive hybridization (SSH) libraries after immune stimulation of mussel Mytilus galloprovincialis. However, to date, the expression pattern, the antimicrobial activities and the immunomodulatory properties of the Myt C peptide have not been determined. In contrast, it is known that Myt C mRNA presents an unusual and high level of polymorphism of unidentified biological significance. Therefore, to provide a better understanding of the features of this interesting molecule, we have investigated its function using four different cloned and expressed variants of Myt C cDNA and polyclonal anti-Myt C sera. The in vivo results suggest that this AMP, mainly present in hemocytes, could be acting as an immune system modulator molecule because its overexpression was able to alter the expression of mussel immune-related genes (as the antimicrobial peptides Myticin B and Mytilin B, the C1q domain-containing protein MgC1q, and lysozyme). Moreover, the in vitro results indicate that Myt C peptides have antimicrobial and chemotactic properties. Their recombinant expression in a fish cell line conferred protection against two different fish viruses (enveloped and non-enveloped). Cell extracts from Myt C expressing fish cells were also able to attract hemocytes. All together, these results suggest that Myt C should be considered not only as an AMP but also as the first chemokine/cytokine-like molecule identified in bivalves and one of the few examples in all of the invertebrates

Synthesis of 5-Hydroxyectoine from Ectoine: Crystal Structure of the Non-Heme Iron(II) and 2-Oxoglutarate-Dependent Dioxygenase EctD

As a response to high osmolality, many microorganisms synthesize various types of compatible solutes. These organic osmolytes aid in offsetting the detrimental effects of low water activity on cell physiology. One of these compatible solutes is ectoine. A sub-group of the ectoine producer's enzymatically convert this tetrahydropyrimidine into a hydroxylated derivative, 5-hydroxyectoine. This compound also functions as an effective osmostress protectant and compatible solute but it possesses properties that differ in several aspects from those of ectoine. The enzyme responsible for ectoine hydroxylation (EctD) is a member of the non-heme iron(II)-containing and 2-oxoglutarate-dependent dioxygenases (EC 1.14.11). These enzymes couple the decarboxylation of 2-oxoglutarate with the formation of a high-energy ferryl-oxo intermediate to catalyze the oxidation of the bound organic substrate. We report here the crystal structure of the ectoine hydroxylase EctD from the moderate halophile Virgibacillus salexigens in complex with Fe3+ at a resolution of 1.85 Å. Like other non-heme iron(II) and 2-oxoglutarate dependent dioxygenases, the core of the EctD structure consists of a double-stranded β-helix forming the main portion of the active-site of the enzyme. The positioning of the iron ligand in the active-site of EctD is mediated by an evolutionarily conserved 2-His-1-carboxylate iron-binding motif. The side chains of the three residues forming this iron-binding site protrude into a deep cavity in the EctD structure that also harbours the 2-oxoglutarate co-substrate-binding site. Database searches revealed a widespread occurrence of EctD-type proteins in members of the Bacteria but only in a single representative of the Archaea, the marine crenarchaeon Nitrosopumilus maritimus. The EctD crystal structure reported here can serve as a template to guide further biochemical and structural studies of this biotechnologically interesting enzyme family

History, epidemiology and regional diversities of urolithiasis

Archeological findings give profound evidence that humans have suffered from kidney and bladder stones for centuries. Bladder stones were more prevalent during older ages, but kidney stones became more prevalent during the past 100 years, at least in the more developed countries. Also, treatment options and conservative measures, as well as ‘surgical’ interventions have also been known for a long time. Our current preventive measures are definitively comparable to those of our predecessors. Stone removal, first lithotomy for bladder stones, followed by transurethral methods, was definitively painful and had severe side effects. Then, as now, the incidence of urolithiasis in a given population was dependent on the geographic area, racial distribution, socio-economic status and dietary habits. Changes in the latter factors during the past decades have affected the incidence and also the site and chemical composition of calculi, with calcium oxalate stones being now the most prevalent. Major differences in frequency of other constituents, particularly uric acid and struvite, reflect eating habits and infection risk factors specific to certain populations. Extensive epidemiological observations have emphasized the importance of nutritional factors in the pathogenesis of urolithiasis, and specific dietary advice is, nowadays, often the most appropriate for prevention and treatment of urolithiasis

Validation of DM-Scan, a computer-assisted tool to assess mammographic density in full-field digital mammograms

We developed a semi-automated tool to assess mammographic density (MD), a phenotype risk marker for breast cancer (BC), in full-field digital images and evaluated its performance testing its reproducibility, comparing our MD estimates with those obtained by visual inspection and using Cumulus, verifying their association with factors that influence MD, and studying the association between MD measures and subsequent BC risk. Three radiologists assessed MD using DM-Scan, the new tool, on 655 processed images (craniocaudal view) obtained in two screening centers. Reproducibility was explored computing pair-wise concordance correlation coefficients (CCC). The agreement between DM-Scan estimates and visual assessment (semi- uantitative scale, 6 categories) was quantified computing weighted kappa statistics (quadratic weights). DM-Scan and Cumulus readings were compared using CCC. Variation of DM-Scan measures by age, body mass index (BMI) and other MD modifiers was tested in regression mixed models with mammographic device as a random-effect term. The association between DM-Scan measures and subsequent BC was estimated in a case control study. All BC cases in screening attendants (2007 2010) at a center with full-field digital mammography were matched by age and screening year with healthy controls (127 pairs). DM-Scan was used to blindly assess MD in available mammograms (112 cases/119 controls). Unconditional logistic models were fitted, including age, menopausal status and BMI as confounders. DM-Scan estimates were very reliable (pairwise CCC: 0.921, 0.928 and 0.916). They showed a reasonable agreement with visual MD assessment (weighted kappa ranging 0.79-0.81). DM-Scan and Cumulus measures were highly concordant (CCC ranging 0.80-0.84), but ours tended to be higher (4%-5% on average). As expected, DM-Scan estimates varied with age, BMI, parity and family history of BC. Finally, DM-Scan measures were significantly associated with BC (p-trend=0.005). Taking MD=29%=3.10 (95% CI=1.35-7.14). Our results confirm that DM-Scan is a reliable tool to assess MD in full-field digital mammograms.This work was supported by research grants from Spain's Health Research Fund (Fondo de INvestigacion Santiaria) (PI060386 & PI09/1230); Gent per Gent Fund (EDEMAC Project) and the Spanish Federation of Breast Cancer Patients (Federacion Espanola de Cancer de Mama) (FECMA 485 EPY 1170-10).Pollán, M.; Llobet Azpitarte, R.; Miranda García, J.; Antón Guirao, J.; Casals El Busto, M.; Martinez Gomez, I.; Palop Jonquères, C.... (2013). Validation of DM-Scan, a computer-assisted tool to assess mammographic density in full-field digital mammograms. SpringerPlus. 2(242):1-13. https://doi.org/10.1186/2193-1801-2-242S1132242Ascunce N, Salas D, Zubizarreta R, Almazan R, Ibanez J, Ederra M: Cancer screening in Spain. Ann Oncol 2010, 21(Suppl 3):iii43-iii51.Assi V, Warwick J, Cuzick J, Duffy SW: Clinical and epidemiological issues in mammographic density. Nat Rev Clin Oncol 2012, 9: 33-40.Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1: 307-310.Boyd NF, Martin LJ, Yaffe MJ, Minkin S: Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011, 13: 223. 10.1186/bcr2942Byng JW, Yaffe MJ, Jong RA, Shumak RS, Lockwood GA, Tritchler DL, Boyd NF: Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 1998, 18: 1587-1598.Cabanes A, Pastor-Barriuso R, Garcia-Lopez M, Pedraz-Pingarron C, Sanchez-Contador C, Vazquez Carrete JA, Moreno MP, Vidal C, Salas D, Miranda-Garcia J, et al.: Alcohol, tobacco, and mammographic density: a population-based study. Breast Cancer Res Treat 2011, 129: 135-147. 10.1007/s10549-011-1414-5Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM: Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case–control study. J Natl Cancer Inst 2011, 103: 744-752. 10.1093/jnci/djr079Evans DG, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, et al.: Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prev Res (Phila) 2012, 5: 943-951. 10.1158/1940-6207.CAPR-11-0458Garrido-Estepa M, Ruiz-Perales F, Miranda J, Ascunce N, Gonzalez-Roman I, Sanchez-Contador C, Santamarina C, Moreo P, Vidal C, Peris M, et al.: Evaluation of mammographic density patterns: reproducibility and concordance among scales. BMC Cancer 2010, 10: 485.Harvey JA: Quantitative assessment of percent breast density: analog versus digital acquisition. Technol Cancer Res Treat 2004, 3: 611-616.Highnam RP, Brady JM, Shepstone BJ: Estimation of compressed breast thickness during mammography. Br J Radiol 1998, 71: 646-653.Keller BM, Nathan DL, Gavenonis SC, Chen J, Conant EF, Kontos D: Reader variability in breast density estimation from full-field digital mammograms: the effect of image postprocessing on relative and absolute measures. Acad Radiol 2013. Epub ahead of printLi J, Szekely L, Eriksson L, Heddson B, Sundbom A, Czene K, Hall P, Humphreys K: High-throughput mammographic-density measurement: a tool for risk prediction of breast cancer. Breast Cancer Res 2012, 14: R114. 10.1186/bcr3238Lin LI: A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989, 45: 255-268. 10.2307/2532051Manduca A, Carston MJ, Heine JJ, Scott CG, Pankratz VS, Brandt KR, Sellers TA, Vachon CM, Cerhan JR: Texture features from mammographic images and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18: 837-845. 10.1158/1055-9965.EPI-08-0631McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15: 1159-1169. 10.1158/1055-9965.EPI-06-0034Nielsen M, Karemore G, Loog M, Raundahl J, Karssemeijer N, Otten JD, Karsdal MA, Vachon CM, Christiansen C: A novel and automatic mammographic texture resemblance marker is an independent risk factor for breast cancer. Cancer Epidemiol 2011, 35: 381-387. 10.1016/j.canep.2010.10.011Olson JE, Sellers TA, Scott CG, Schueler BA, Brandt KR, Serie DJ, Jensen MR, Wu FF, Morton MJ, Heine JJ, et al.: The influence of mammogram acquisition on the mammographic density and breast cancer association in the mayo mammography health study cohort. Breast Cancer Res 2012, 14: R147. 10.1186/bcr3357Perez-Gomez B, Ruiz F, Martinez I, Casals M, Miranda J, Sanchez-Contador C, Vidal C, Llobet R, Pollan M, Salas D: Women's features and inter-/intra-rater agreement on mammographic density assessment in full-field digital mammograms (DDM-SPAIN). Breast Cancer Res Treat 2012, 132: 287-295. 10.1007/s10549-011-1833-3Pollan M, Lope V, Miranda-Garcia J, Garcia M, Casanova F, Sanchez-Contador C, Santamarina C, Moreo P, Vidal C, Peris M, et al.: Adult weight gain, fat distribution and mammographic density in Spanish pre- and post-menopausal women (DDM-Spain). Breast Cancer Res Treat 2012, 134: 823-838. 10.1007/s10549-012-2108-3Sala M, Salas D, Belvis F, Sanchez M, Ferrer J, Ibanez J, Roman R, Ferrer F, Vega A, Laso MS, et al.: Reduction in false-positive results after introduction of digital mammography: analysis from four population-based breast cancer screening programs in Spain. Radiology 2011, 258: 388-395. 10.1148/radiol.10100874Schousboe JT, Kerlikowske K, Loh A, Cummings SR: Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med 2011, 155: 10-20. 10.7326/0003-4819-155-1-201107050-00003Stone J, Ding J, Warren RM, Duffy SW, Hopper JL: Using mammographic density to predict breast cancer risk: dense area or percentage dense area. Breast Cancer Res 2010, 12: R97. 10.1186/bcr2778Vachon CM, Brandt KR, Ghosh K, Scott CG, Maloney SD, Carston MJ, Pankratz VS, Sellers TA: Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007, 16: 43-49. 10.1158/1055-9965.EPI-06-0738Vachon C, Fowler EE, Tiffenberg G, Scott C, Pankratz VS, Sellers TA, Heine JJ: Comparison of percent density from raw and processed full field digital mammography data. Breast Cancer Res 2013, 15: R1. 10.1186/bcr3372Yaffe MJ: Mammographic density. Measurement of mammographic density. Breast Cancer Res 2008, 10: 209. 10.1186/bcr2102Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, Tamimi RM: Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst 2011, 103: 1179-1189. 10.1093/jnci/djr22

EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI) : Study protocol for a multicentre, observational trial

More than 300 million surgical procedures are performed each year. Acute kidney injury (AKI) is a common complication after major surgery and is associated with adverse short-term and long-term outcomes. However, there is a large variation in the incidence of reported AKI rates. The establishment of an accurate epidemiology of surgery-associated AKI is important for healthcare policy, quality initiatives, clinical trials, as well as for improving guidelines. The objective of the Epidemiology of Surgery-associated Acute Kidney Injury (EPIS-AKI) trial is to prospectively evaluate the epidemiology of AKI after major surgery using the latest Kidney Disease: Improving Global Outcomes (KDIGO) consensus definition of AKI. EPIS-AKI is an international prospective, observational, multicentre cohort study including 10 000 patients undergoing major surgery who are subsequently admitted to the ICU or a similar high dependency unit. The primary endpoint is the incidence of AKI within 72 hours after surgery according to the KDIGO criteria. Secondary endpoints include use of renal replacement therapy (RRT), mortality during ICU and hospital stay, length of ICU and hospital stay and major adverse kidney events (combined endpoint consisting of persistent renal dysfunction, RRT and mortality) at day 90. Further, we will evaluate preoperative and intraoperative risk factors affecting the incidence of postoperative AKI. In an add-on analysis, we will assess urinary biomarkers for early detection of AKI. EPIS-AKI has been approved by the leading Ethics Committee of the Medical Council North Rhine-Westphalia, of the Westphalian Wilhelms-University Münster and the corresponding Ethics Committee at each participating site. Results will be disseminated widely and published in peer-reviewed journals, presented at conferences and used to design further AKI-related trials. Trial registration number NCT04165369